膝下动脉干预的慢性肢体威胁性缺血:旁路手术与腔内治疗的比较
基于VQI注册研究2017至2022年膝下动脉干预的CLTI患者,经倾向性评分匹配比较旁路手术(BP)与腔内治疗(EVT)。BP与EVT的无截肢生存(AFS)相当,但BP总生存更优而保肢更差;自体静脉旁路(BPAV)AFS和总生存优于EVT且保肢相当;人工血管旁路(BPPC)AFS和保肢劣于EVT但总生存更高。
要点
- BP与EVT的2年AFS相当,BP总生存更优但保肢更差。
- 自体静脉旁路(尤其大隐静脉)AFS和总生存优于EVT,保肢相当。
- 无自体静脉时,积极EVT可能因AFS和保肢更优而合理。
核心结论
- 在可行情况下,自体静脉旁路(尤其大隐静脉)应优先于EVT,因其AFS和总生存更优且保肢相当。
- 无自体静脉时,积极EVT可能合理,因其AFS和保肢优于人工血管旁路。
研究设计与样本
- 基于Vascular Quality Initiative外周血管干预和腹股沟下旁路注册研究2017至2022年所有因CLTI行膝下动脉干预的病例。
- 识别出风险特征显著不同的19,505例EVT和9,185例BP患者,构建倾向性评分匹配队列比较EVT与BP、BPAV及BPPC。
主要发现
- 匹配后BP与EVT的2年AFS为50.3% vs. 49.0%(HR截肢/死亡0.947 [0.876-1.024],P=0.229),2年总生存79.7% vs. 75.6%(HR全因死亡0.841 [0.761-0.928],P=0.002),2年免于大截肢71.4% vs. 81.4%(HR大截肢1.432 [1.266-1.620],P<0.001)。
- BPAV(91%为大隐静脉旁路)与EVT相比,2年AFS为53.9% vs. 52.5%(HR截肢/死亡0.854 [0.778-0.938],P<0.001),2年总生存81.1% vs. 77.4%(HR全因死亡0.872 [0.776-0.980],P=0.015),2年免于大截肢76.0% vs. 81.4%(HR大截肢1.102 [0.951-1.278],P=0.353)。
- BPPC与EVT相比,2年AFS为44.1% vs. 46.9%(HR截肢/死亡1.279 [1.126-1.452],P=0.001),2年免于大截肢63.3% vs. 77.5%(HR大截肢2.165 [1.780-2.633],P<0.001),2年总生存78.8% vs. 75.8%(HR全因死亡0.837 [0.706-0.992],P=0.012)。
临床怎么用
- 对需膝下干预的CLTI患者,若有可用的自体静脉(尤其大隐静脉),应优先考虑旁路手术而非EVT。
- 若无自体静脉可用,可考虑积极EVT,因其AFS和保肢优于人工血管旁路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Chronic Limb Threatening Ischemia (CLTI) involving the crural arteries is clinically and anatomically challenging. The BASIL-2 trial and a subanalysis of the BEST-CLI trial examined the efficacy of endovascular therapy (EVT) versus surgical bypass (BP) among this cohort, but arrived at differing conclusions. This study aimed to compare the outcomes of EVT and surgical bypass among patients with CLTI requiring infra-popliteal interventions in a real-world registry. METHODS: All infra-popliteal procedures performed for CLTI were identified in the peripheral vascular intervention and infra-inguinal bypass registries of the Vascular Quality Initiative (VQI) from 2017 to 2022. Patients were identified with significantly different risk profiles (19,505 EVT and 9,185 BP). Propensity score-matched cohorts were constructed to compare EVT versus BP, BP with autologous vein (BPAV), and BP with prosthetic conduit (BPPC). Amputation-free survival (AFS), overall survival (OS), and freedom from major amputation were examined. RESULTS: 5,236 well-matched pairs of EVT versus BP, 3,892 well-matched pairs of EVT versus BPAV, and 1,971 well-matched pairs of EVT versus BPPC were included. BP and EVT demonstrated equivalent AFS (2-year AFS: 50.3% vs. 49.0%, HR amputation/death: 0.947 [0.876-1.024], P = 0.229), which was due to superior OS in the BP group (2-year OS: 79.7% vs. 75.6%, HR all-cause mortality: 0.841 [0.761-0.928] P = 0.002) matched by inferior limb salvage in the BP group (2-year freedom from major amputation: 71.4% vs. 81.4%, HR major amputation: 1.432 [1.266-1.620], P < 0.001). BPAV, composed primarily (91%) of great saphenous vein bypass (GSV BP), was associated with significantly greater AFS than EVT (2-year AFS: 53.9% vs. 52.5%, HR amputation/death: 0.854 [0.778-0.938], P < 0.001), which was driven by greater OS (2-year OS: 81.1% vs. 77.4%, HR all-cause mortality: 0.872 [0.776-0.980], P = 0.015) with equivalent limb salvage (2-year freedom from major amputation: 76.0% vs. 81.4%, HR major amputation: 1.102 [0.951-1.278], P = 0.353). However, BPPC was associated with significantly lower AFS than EVT (2-year AFS: 44.1% vs. 46.9%, HR amputation/death: 1.279 [1.126-1.452], P = 0.001), which was driven inferior limb salvage in the BPPC group (2-year freedom from major amputation: 63.3% vs. 77.5%, HR major amputation: 2.165 [1.780-2.633], P < 0.001) despite higher OS in the BPPC group (2-year OS: 78.8% vs. 75.8%, HR all-cause mortality: 0.837 [0.706-0.992], P = 0.012). CONCLUSION: When feasible, BPAV (particularly with GSV) should be considered over EVT due to superior AFS and OS with equivalent limb salvage. However, when autologous vein is unavailable, an aggressive approach to EVT may be warranted due to superior AFS and limb salvage despite slightly higher OS in the BPPC group.
引用
- Bloch RA, Lin A, Caron E, et al. Bypass versus Endovascular Therapy in Chronic Limb Threatening Ischemia Requiring Infra-Popliteal Interventions. Ann Vasc Surg. 2025. PMID: 40653193. doi:10.1016/j.avsg.2025.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。